DALLAS, May 18, 2020 — Treatment with antibodies purified from donated blood – immune globulin therapy – and steroids restored heart function in the majority of  children with COVID-related multisystem inflammatory syndrome, according to new research published yesterday in Circulation, the flagship journal of the American Heart Association.

Physicians around the world have recently noted that a small number of children exposed to  COVID-19 have an emerging condition with features overlapping toxic shock syndrome and similar to a heart condition known as Kawasaki disease, together with cardiac inflammation. The symptoms most commonly observed are high-spiking fever, unusual lethargy over several days (asthenia), digestive signs including severe abdominal pain, vomiting or diarrhea, swollen lymph nodes (adenopathy) and skin rash.

In this small study, “Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic,” researchers in France and Switzerland retrospectively collected and analyzed clinical, biological, therapeutic and early outcome data for children admitted to the pediatric intensive care unit from March 22 to April 30, 2020, with fever, cardiogenic shock or acute left ventricular dysfunction with inflammatory state.

This analysis included 35 children (ages 2 to 16; median age of 10 years). Thirty-one (88.5%) children tested positive for SARS-CoV-2 infection, and none of the children had underlying cardiovascular disease. Secondary conditions were limited, and 17% of patients were overweight (n=6). All patients presented with fever and unusual lethargy (asthenia) lasting approximately 2 days, and 83% of patients (n=29) presented with gastrointestinal symptoms.

Left ventricular systolic dysfunction was present in all patients in association with low systolic blood pressure. Almost all patients required respiratory assistance (n= 33). Left ventricular function recovered in the majority of patients discharged from the intensive care unit (n=25). Ten patients treated with ECMO (extracorporeal membrane oxygenation) for 3-6 days were successfully weaned. (ECMO is a process whereby the blood is sent through a machine to increase the amount of oxygen in the blood. The oxygen-rich blood is then returned to the body.)

The majority of patients received intravenous immune globulin treatment (n=25), and 12 patients were treated with intravenous steroids. Three children were treated with an interleukin 1 receptor antagonist due to persistent severe inflammatory state. 23 patients were treated with a therapeutic dose of heparin. No deaths were observed.

“The majority of patients recovered within a few days following intravenous immune globulin, with adjunctive steroid therapy used in one third. Treatment with immune globulin appears to be associated with recovery of left ventricular systolic function,”  researchers reported.

The researchers’ key findings are:

  • Multisystem Inflammatory Syndrome in Children (MIS-C) is a new syndrome that appears to be temporally related to previous exposure to SARS-CoV-2.
  • MIS-C shares similarities with atypical Kawasaki disease, but prominent clinical signs are largely different.
  • Myocardial involvement with acute heart failure is likely due to myocardial stunning or edema rather than to inflammatory myocardial damage.
  • Whereas the initial presentation may be severe with some patients requiring circulatory and respiratory mechanical assistance, rapid recovery with the use of immune globulin and steroids is currently observed.
  • Early diagnosis and management appear to lead to favorable outcome using classical therapies.
  • Additional study is needed to determine the full spectrum of the illness and whether long-term cardiac complications may arise.

Authors are Zahra Belhadjer, M.D.; Mathilde Méot, M.D.; Fanny Bajolle, M.D., Ph.D.; Diala Khraiche, M.D.; Antoine Legendre, M.D.; Samya Abakka, M.D.; Johanne Auriau, M.D., Ph.D.; Marion Grimaud, M.D.; Mehdi Oualha, M.D., Ph.D.; Maurice Beghetti, M.D., Ph.D.; Julie Wacker, M.D.; Caroline Ovaert, M.D., Ph.D.; Sebastien Hascoet, M.D.; Maëlle Selegny, M.D.; Sophie Malekzadeh-Milani, M.D.; Alice Maltret, M.D.; Gilles Bosser, M.D., Ph.D.; Nathan Giroux, M.D.; Laurent Bonnemains, M.D., Ph.D.; Jeanne Bordet, M.D., Ph.D.; Sylvie Di Filippo, M.D., Ph.D.; Pierre Mauran, M.D., Ph.D; Sylvie Falcon-Eicher, M.D.; Jean-Benoît Thambo, M.D., Ph.D.; Bruno Lefort, M.D., Ph.D.; Pamela Moceri, M.D., Ph.D.; Lucile Houyel, M.D., Ph.D.; Sylvain Renolleau, M.D., Ph.D.; and Damien Bonnet, M.D., Ph.D. The authors have no disclosures.

Additional Resources:

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.


For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173

Michelle Kirkwood: 703-457-7838; michelle.kirkwood@heart.org

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and strokeassociation.org